Literature DB >> 9713979

Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats.

S Agrawal1, X Zhang, Q Cai, E R Kandimalla, A Manning, Z Jiang, T Marcel, R Zhang.   

Abstract

Pharmacokinetic studies of phosphorothioate oligodeoxynucleotides (PS-oligonucleotides) in animals show that following intravenous administration, PS-oligonucleotide clears out rapidly from the plasma and is distributed to majority of the organs. PS-oligonucleotides are bound to plasma proteins extensively. This study was aimed to determine the effect of aspirin, a commonly used drug, on pharmacokinetics of PS-oligonucleotides. In the present study, PS-oligonucleotide was administered to rats that had received aspirin by gavage. Pharmacokinetic study shows that if PS-oligonucleotide was administered following aspirin administration in rats, a) plasma pharmacokinetic parameters (t1/2alpha?, t1/2beta, AUC, etc.) had lower values, b) tissue disposition was different, and c) rate and route of elimination was affected in animals compared to rats receiving PS-oligonucleotide alone. This finding suggests that pharmacokinetics of PS-oligonucleotides can be affected with certain class of drugs, which may have direct impact on biological activity and safety.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713979     DOI: 10.3109/10611869808995883

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  8 in total

1.  Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent.

Authors:  Elizabeth Rayburn; Wei Wang; Mao Li; Xu Zhang; Hongxia Xu; Haibo Li; Jiang-Jiang Qin; Lee Jia; Joseph Covey; Moses Lee; Ruiwen Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2012-02-25       Impact factor: 3.333

2.  Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice.

Authors:  Subhasree Nag; Jiang-Jiang Qin; Sukesh Voruganti; Ming-Hai Wang; Horrick Sharma; Shivaputra Patil; John K Buolamwini; Wei Wang; Ruiwen Zhang
Journal:  Biomed Chromatogr       Date:  2014-10-08       Impact factor: 1.902

3.  Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.

Authors:  R Z Yu; R S Geary; J M Leeds; T Watanabe; J R Fitchett; J E Matson; R Mehta; G R Hardee; M V Templin; K Huang; M S Newman; Y Quinn; P Uster; G Zhu; P K Working; M Horner; J Nelson; A A Levin
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

Review 4.  Fomivirsen: clinical pharmacology and potential drug interactions.

Authors:  Richard S Geary; Scott P Henry; Lisa R Grillone
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Introduction and History of the Chemistry of Nucleic Acids Therapeutics.

Authors:  Michael J Gait; Sudhir Agrawal
Journal:  Methods Mol Biol       Date:  2022

6.  Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.

Authors:  Scharri J Ezell; Haibo Li; Hongxia Xu; Xiangrong Zhang; Evrim Gurpinar; Xu Zhang; Elizabeth R Rayburn; Charnell I Sommers; Xinyi Yang; Sadanandan E Velu; Wei Wang; Ruiwen Zhang
Journal:  Mar Drugs       Date:  2010-07-13       Impact factor: 5.118

7.  KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Authors:  Wei Wang; Lin Ao; Elizabeth R Rayburn; Hongxia Xu; Xiangrong Zhang; Xu Zhang; Subhasree Ashok Nag; Xuming Wu; Ming-Hai Wang; Hui Wang; Erwin G Van Meir; Ruiwen Zhang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

Review 8.  The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.

Authors:  Sudhir Agrawal
Journal:  Biomedicines       Date:  2021-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.